GlassScriptPhysician profile
Mary O Polk
NPI 1427158104
$10,564.82
in general payments reported to CMS, 2019-2025
43 companies · $2,784 in 2025
The $2,784 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $499 · 2021: $632 · 2022: $1,006 · 2023: $1,659 · 2024: $3,023 · 2025: $2,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,518 · Travel and Lodging: $914 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,518.32 |
| Travel and Lodging | $914.04 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,453.77 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,250.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Inspire Medical Systems, INC. | $1,083.00 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $640.41 | 2019-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $550.06 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Grifols USA, LLC | $533.15 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $487.14 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $483.91 | 2021-2025 | Glassia, Cuvitru |
| Insmed, INC. | $478.32 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.69 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| United Therapeutics Corporation | $419.25 | 2022-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $336.89 | 2019-2025 | |
| Amgen INC. | $332.64 | 2022-2025 | Tezspire |
| Verona Pharma, INC. | $265.00 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $188.12 | 2025 | Yupelri |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $167.01 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Inari Medical, INC. | $146.42 | 2022 | |
| Mallinckrodt Hospital Products INC. | $142.91 | 2020-2025 | Acthar |
| Philips North America LLC | $131.37 | 2019-2022 | |
| Abiomed | $111.41 | 2024 | Impella |
| Sunovion Pharmaceuticals INC. | $88.10 | 2019 | |
| Fisher & Paykel Healthcare INC | $86.40 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $81.99 | 2024-2025 | Purified Cortrophin Gel |
| Resmed Corp | $75.82 | 2025 | |
| Pulmonx Corporation | $65.53 | 2019-2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Shire North American Group INC | $58.64 | 2019 | |
| Ethicon INC. | $57.01 | 2024 | Monarch Platform |
| Genentech USA, INC. | $54.41 | 2020-2022 | |
| Masimo Corporation | $42.96 | 2019 | |
| Lilly USA, LLC | $32.09 | 2025 | Zepbound |
| Merck Sharp & Dohme LLC | $31.51 | 2022-2024 | Keytruda |
| Advanced Respiratory, INC | $27.59 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.10 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $19.46 | 2021 | |
| Itamar Medical INC | $19.12 | 2025 | Watchpatone |
| Abbvie INC. | $18.40 | 2024 | |
| Circassia INC. | $17.55 | 2019 | |
| Cvrx, INC. | $16.94 | 2025 | Barostim Neo System |
| Mallinckrodt Enterprises LLC | $16.85 | 2019 | |
| Phadia US INC. | $16.44 | 2023 | Immunocap |
| Paratek Pharmaceuticals, INC. | $16.03 | 2024 | Nuzyra |
| Tactile Systems Technology INC | $14.93 | 2025 | Nimbl, Flexitouch Plus |
| Novartis Pharmaceuticals Corporation | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Polk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.